Sunovion's Seizure Drug Aptiom Wins Monotherapy Use
This article was originally published in Scrip
Marlborough, Massachusetts-based Sunovion Pharmaceuticals won the FDA's approval to market Aptiom (eslicarbazepine acetate) as monotherapy to treat partial-onset seizures.
You may also be interested in...
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.